Review
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Clin Cases. Dec 16, 2013; 1(9): 262-275
Published online Dec 16, 2013. doi: 10.12998/wjcc.v1.i9.262
Renal cell carcinoma: Evolving and emerging subtypes
Suzanne M Crumley, Mukul Divatia, Luan Truong, Steven Shen, Alberto G Ayala, Jae Y Ro
Suzanne M Crumley, Mukul Divatia, Luan Truong, Steven Shen, Alberto G Ayala, Jae Y Ro, Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Cornell Medical College of Cornell University, Houston, TX 77030, United States
Author contributions: Crumley SM and Divatia M contributed equally to the writing of the text and revisions of the manuscript; Truong L contributed to the revisions and some of the photographs in the figures; Shen S and Ayala AG contributed to the revisions and editing of the manuscript; Ro JY contributed to the conception and revisions of the manuscript.
Correspondence to: Jae Y Ro, MD, PhD, Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Cornell Medical College of Cornell University, 6565 Fannin Street, Suite M227, Houston, TX 77030, United States. jaero@tmhs.org
Telephone: +1-713-4412263 Fax: +1-972-6974622
Received: September 17, 2013
Revised: November 3, 2013
Accepted: December 9, 2013
Published online: December 16, 2013
Processing time: 174 Days and 12.6 Hours
Core Tip

Core tip: New concepts in selected renal cell carcinoma (RCC) subtypes are reviewed. We describe evolving concepts in Xp11 translocation carcinoma, mucinous tubular and spindle cell carcinoma, multilocular cystic clear cell RCC, and carcinoma associated with neuroblastoma. Additionally, tubulocystic carcinoma, thyroid-like follicular carcinoma of kidney, acquired cystic disease-associated RCC, and clear cell papillary RCC are described. Finally, candidate entities, including RCC with t(6;11) translocation, hybrid oncocytoma/chromophobe RCC, hereditary leiomyomatosis and RCC syndrome, and renal angiomyoadenomatous tumor are discussed. This review provides a targeted summary of recent updates for those who diagnose and treat renal cancer.